AU2022320615B2 - 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer - Google Patents

1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer

Info

Publication number
AU2022320615B2
AU2022320615B2 AU2022320615A AU2022320615A AU2022320615B2 AU 2022320615 B2 AU2022320615 B2 AU 2022320615B2 AU 2022320615 A AU2022320615 A AU 2022320615A AU 2022320615 A AU2022320615 A AU 2022320615A AU 2022320615 B2 AU2022320615 B2 AU 2022320615B2
Authority
AU
Australia
Prior art keywords
administration
gedatolisib
period
inhibitor
cycles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022320615A
Other languages
English (en)
Other versions
AU2022320615A1 (en
Inventor
Lance Gavin LAING
Brian Francis Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celcuity Inc
Original Assignee
Celcuity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celcuity Inc filed Critical Celcuity Inc
Publication of AU2022320615A1 publication Critical patent/AU2022320615A1/en
Application granted granted Critical
Publication of AU2022320615B2 publication Critical patent/AU2022320615B2/en
Priority to AU2025223785A priority Critical patent/AU2025223785A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022320615A 2021-07-26 2022-07-25 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer Active AU2022320615B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025223785A AU2025223785A1 (en) 2021-07-26 2025-08-27 1-(4-{[4-(Dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163225707P 2021-07-26 2021-07-26
US63/225,707 2021-07-26
US202163285327P 2021-12-02 2021-12-02
US63/285,327 2021-12-02
PCT/US2022/038188 WO2023009438A1 (en) 2021-07-26 2022-07-25 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025223785A Division AU2025223785A1 (en) 2021-07-26 2025-08-27 1-(4-{[4-(Dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2022320615A1 AU2022320615A1 (en) 2024-03-14
AU2022320615B2 true AU2022320615B2 (en) 2025-08-21

Family

ID=82932627

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022320615A Active AU2022320615B2 (en) 2021-07-26 2022-07-25 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
AU2025223785A Pending AU2025223785A1 (en) 2021-07-26 2025-08-27 1-(4-{[4-(Dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025223785A Pending AU2025223785A1 (en) 2021-07-26 2025-08-27 1-(4-{[4-(Dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer

Country Status (11)

Country Link
US (3) US12350276B2 (cg-RX-API-DMAC7.html)
EP (1) EP4376848A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024529430A (cg-RX-API-DMAC7.html)
KR (1) KR20240040768A (cg-RX-API-DMAC7.html)
AU (2) AU2022320615B2 (cg-RX-API-DMAC7.html)
CA (1) CA3227191A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000208A1 (cg-RX-API-DMAC7.html)
IL (1) IL310243A (cg-RX-API-DMAC7.html)
MX (1) MX2024001266A (cg-RX-API-DMAC7.html)
TW (1) TW202320795A (cg-RX-API-DMAC7.html)
WO (1) WO2023009438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025049962A1 (en) * 2023-08-31 2025-03-06 Aadi Bioscience, Inc. Combination cancer treatments with a composition comprising an mtor pathway inhibitor
US20260053814A1 (en) * 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
JP5190271B2 (ja) 2005-01-14 2013-04-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としての5員の環付加複素環式ピリミジン
US10022381B2 (en) 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
MY155653A (en) 2008-05-23 2015-11-13 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
KR102186969B1 (ko) 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
EP3216792B1 (en) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactam kinase inhibitors
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
EP3116547B1 (en) 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
HUE055928T2 (hu) 2014-12-17 2022-01-28 Pfizer PI3K/MTOR-inhibitorok készítményei intravénás adagolásra
LT3672571T (lt) 2017-08-25 2021-12-10 Pfizer Inc. Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą
US12109308B2 (en) 2018-06-07 2024-10-08 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yljcarbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
EP3863618A1 (en) * 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Methods of treating cancer with pi3k alpha inhibitors and metformin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FORERO A ET AL: "Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant...", CANCER RESEARCH, vol. 78, no. 4, Supplement 1, 1 February 2018 *
FORERO-TORRES A ET AL: "Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with ER+ metastatic breast cancer (MBC)", JOURNAL OF CLINICAL ONCOLOGY, vol. 36, no. 15, Supplement 1, 1 May 2018 *

Also Published As

Publication number Publication date
US20260174772A1 (en) 2026-06-25
CL2024000208A1 (es) 2024-07-19
KR20240040768A (ko) 2024-03-28
EP4376848A1 (en) 2024-06-05
AU2022320615A1 (en) 2024-03-14
JP2024529430A (ja) 2024-08-06
TW202320795A (zh) 2023-06-01
IL310243A (en) 2024-03-01
US20230022525A1 (en) 2023-01-26
CA3227191A1 (en) 2023-02-02
WO2023009438A1 (en) 2023-02-02
US20250345342A1 (en) 2025-11-13
US12350276B2 (en) 2025-07-08
MX2024001266A (es) 2024-04-16
AU2025223785A1 (en) 2025-09-18

Similar Documents

Publication Publication Date Title
JP6595024B2 (ja) B−Raf阻害薬、EGFR阻害薬及び場合によってはPI3K−α阻害薬を含む組合せ医薬
RU2737496C2 (ru) Способы лечения рака
CN111032082B (zh) Her2阳性癌症的治疗
US20250345342A1 (en) Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
CN114366743A (zh) 具有驱动致癌突变的癌症的治疗
US20260041695A1 (en) Combination therapies for treatment of breast cancer
JP2021525244A (ja) 腫瘍性疾患を治療するための薬剤の調製におけるegfr阻害剤と組み合わせたcdk4/6阻害剤の使用
JP2014515390A (ja) Pi3k阻害剤化合物を用いた中皮腫の治療法
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
JP2022507686A (ja) 薬学的方法
CN117813097A (zh) 用于治疗癌症的1-(4-{[4-(二甲氨基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二吗啉-4-基-1,3,5-三嗪-2-基)苯基]脲(吉达利塞)及其组合
US20230218618A1 (en) Administration of sumo-activating enzyme inhibitor and anti-cd38 antibodies
US20260053814A1 (en) Treatment regimens for gedatolisib in hormonally-driven disorders
US20240350497A1 (en) Combination therapy for the treatment of pan-kras mutated cancers
TW202532065A (zh) 治療乳癌之組合療法
TW202315635A (zh) 一種藥物組合及其應用
HK40086978A (en) Therapeutic combinations comprising a craf inhibitor
HK40069821B (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
HK40072726A (en) Combination therapies for treatment of breast cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)